Forte Biosciences is a clinical-stage biopharmaceutical company whose lead product candidate is FB102. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company’s FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. In June 2025, we announced positive data in FB102 celiac disease phase 1B study. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). A Phase 2 celiac disease has been initiated with data expected in 2026. Additionally, a Phase 1B vitiligo trial has commenced enrollment with topline results expected in 1H26.